A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, parallel-group, placebo-controlled, and active-drug,
12-week, multicenter clinical study. Participants will be randomized 2: 2: 1 to receive the
combination of glucosamine sulfate + meloxicam (experimental group), combination of
glucosamine sulfate + chondroitin sulfate (active control group) or placebo.